Beyond Air, Inc. (NASDAQ:XAIR) Sees Significant Growth in Short Interest

Beyond Air, Inc. (NASDAQ:XAIR) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,200,000 shares, a growth of 40.8% from the January 31st total of 852,200 shares. Based on an average daily trading volume, of 1,530,000 shares, the days-to-cover ratio is presently 0.8 days.

Hedge Funds Weigh In On Beyond Air

Several institutional investors have recently made changes to their positions in XAIR. Soros Fund Management LLC bought a new position in Beyond Air in the 3rd quarter worth $573,000. Baldwin Wealth Partners LLC MA grew its stake in Beyond Air by 721.3% in the 4th quarter. Baldwin Wealth Partners LLC MA now owns 308,000 shares of the company’s stock worth $110,000 after acquiring an additional 270,500 shares in the last quarter. Squarepoint Ops LLC bought a new position in Beyond Air in the 4th quarter worth about $48,000. Balyasny Asset Management L.P. bought a new position in shares of Beyond Air during the fourth quarter valued at approximately $1,195,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Beyond Air during the fourth quarter valued at approximately $2,560,000. Institutional investors own 31.50% of the company’s stock.

Beyond Air Price Performance

NASDAQ:XAIR opened at $0.26 on Tuesday. Beyond Air has a 1-year low of $0.26 and a 1-year high of $1.99. The firm’s 50-day moving average price is $0.38 and its 200-day moving average price is $0.42. The company has a market capitalization of $17.82 million, a PE ratio of -0.24 and a beta of -0.15.

Beyond Air (NASDAQ:XAIR) last posted its earnings results on Monday, February 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.09. Beyond Air had a negative net margin of 1,730.00% and a negative return on equity of 226.01%. During the same quarter in the previous year, the company posted ($0.50) EPS. Equities analysts anticipate that Beyond Air will post -0.79 EPS for the current fiscal year.

About Beyond Air

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.